WHO ICTRP trial
Clinical Trial of Lurbinectedin as Single-agent or in Combination with…
JPRN-jRCT2071230123 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2071230123 |
|---|---|
| Public title | Clinical Trial of Lurbinectedin as Single-agent or in Combination with Irinotecan Versus Topotecan or Irinotecan in Patients with Relapsed Small-cell Lung Cancer |
| Scientific title | A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer (SCLC) Patients - LAGOON |
| Primary sponsor | Kobayashi Takeshi |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Australia;Japan;South Korea;Japan;Taiwan;Japan;Austria;Japan;Belgium;Japan;Bulgaria;Japan;Switzerland;Japan;Germany;Japan;Denmark;Japan;Spain;Japan;France;Japan;Georgia;Japan;UK;Japan;Hungary;Japan;It… |
| Conditions | Relapsed Small Cell Lung Cancer |
| Interventions | SCLC patients who failed one prior platinum-containing line will be enrolled and assigned to each treatment arm: two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan… |
| Registration date | Mar 13, 2024 |
| Target size | 35 |
| Secondary IDs | 2021-004471-13;NCT05153239 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: